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Chorismate mutase/prephenate dehydrogenase from Haemophilus inﬂuenzae
Rd KW20 is a bifunctional enzyme that catalyzes the rearrangement of
chorismate to prephenate and the NAD(P)
+-dependent oxidative decarboxyl-
ation of prephenate to 4-hydroxyphenylpyruvate in tyrosine biosynthesis. The
crystal structure of the prephenate dehydrogenase component (HinfPDH) of
the TyrA protein from H. inﬂuenzae Rd KW20 in complex with the inhibitor
tyrosine and cofactor NAD
+ has been determined to 2.0 A ˚ resolution. HinfPDH
is a dimeric enzyme, with each monomer consisting of an N-terminal  / 
dinucleotide-binding domain and a C-terminal  -helical dimerization domain.
The structure reveals key active-site residues at the domain interface, including
His200, Arg297 and Ser179 that are involved in catalysis and/or ligand binding
and are highly conserved in TyrA proteins from all three kingdoms of life.
Tyrosine is bound directly at the catalytic site, suggesting that it is a competitive
inhibitor of HinfPDH. Comparisons with its structural homologues reveal
important differences around the active site, including the absence of an  – 
motif in HinfPDH that is present in other TyrA proteins, such as Synechocystis
sp. arogenate dehydrogenase. Residues from this motif are involved in
discrimination between NADP
+ and NAD
+. The loop between  5 and  6i n
the N-terminal domain is much shorter in HinfPDH and an extra helix is present
at the C-terminus. Furthermore, HinfPDH adopts a more closed conformation
compared with TyrA proteins that do not have tyrosine bound. This
conformational change brings the substrate, cofactor and active-site residues
into close proximity for catalysis. An ionic network consisting of Arg297 (a key
residue for tyrosine binding), a water molecule, Asp206 (from the loop between
 5 and  6) and Arg3650 (from the additional C-terminal helix of the adjacent
monomer) is observed that might be involved in gating the active site.
1. Introduction
The TyrA protein family comprises dehydrogenases that are
dedicated to l-tyrosine biosynthesis. These dehydrogenases can be
classiﬁed into three groups according to their substrate speciﬁcity.
Prephenate dehydrogenases (TyrAp or PDH) only use prephenate as
a substrate, arogenate dehydrogenases (TyrAa of ADH) only accept
arogenate and cyclohexadienyl dehydrogenases (TyrAc or CDH) use
either prephenate or arogenate. The TyrA dehydrogenases convert
prephenate to tyrosine through two different routes (Fig. 1). In the
prephenate pathway, PDH enzymes catalyze the NAD(P)
+-depen-
dent oxidative decarboxylation of prephenate to 4-hydroxyphenyl-
pyruvate (HPP), which is then converted to l-tyrosine by an amino-
transferase. In the arogenate route, prephenate is ﬁrst transaminated
to l-arogenate by prephenate aminotransferase. l-Arogenate is then
decarboxylated and converted to l-tyrosine by ADH. In addition to
diverse substrate speciﬁcity, the TyrA family also exhibits diversity
with respect to its cofactor speciﬁcity. TyrA proteins may be speciﬁc
for NAD
+ or NADP
+ or may use both. TyrA proteins exist as either
monofunctional or bifunctional proteins. The common fusion part-
ners of TyrA proteins include chorismate mutase (aroQ; Calhoun
et al., 2001), 3-phosphoshikimate 1-carboxyvinyltransferase (aroF;Beller et al., 2006) and an ACT (aspartate kinase–chorismate mutase–
TyrA) regulatory domain (Chipman & Shaanan, 2001; Grant, 2006).
TyrAp is mostly present in low-GC Gram-positive organisms, such
as Bacillus subtilis. TyrAa is abundant in higher plants and in at least
three bacterial lineages, cyanobacteria, actinomycetes and Nitroso-
monas europaea, whereas TyrAc is found in most bacteria. An
analysis of the phylogenetic relationship of TyrA enzymes identiﬁed a
distinct subgroup within the TyrAc group, denoted here as TyrAc_
(Song et al., 2005). When the primary sequences of these TyrAc_
proteins are aligned with those of other TyrA groups, it is immedi-
ately apparent that the TyrAc_ proteins contain a number of
deletions within the catalytic core region and possess a second
functional domain, which classiﬁes them as bifunctional enzymes.
Biochemical studies have shown that this subgroup displays narrower
substrate and cofactor speciﬁcity compared with the parent TyrAc
enzymes. The TyrA enzymes from Escherichia coli and Klebsiella
pneumoniae are the two best characterized TyrAc_ enzymes and
both prefer prephenate over arogenate by more than one order of
magnitude and only use NAD
+ as cofactor (Ahmad & Jensen, 1987;
Turnbull et al., 1990). The studies further suggested that the TyrAc
family, with its broad substrate speciﬁcity, represents the ancestral
enzymes from which the TyrAc_, TyrAa and TyrAp enzymes have
evolved to exhibit a narrower range of substrate speciﬁcity (Song et
al., 2005).
The regulation of TyrA activity is important as prephenate is a
common precursor in the biosynthesis of tyrosine and phenylalanine.
TyrA enzymes are regulated by various mechanisms, including
feedback inhibition and gene regulation by the Tyr operon (Cobbett
& Delbridge, 1987). Kinetic studies of chorismate mutase/prephenate
dehydrogenase (CM/PDH) from E. coli have led to the proposal of
two different types of mechanism for tyrosine inhibition. Christo-
pherson (1985) concluded that tyrosine acts as a competitive inhibitor
in the dehydrogenase reaction, whereas Turnbull, Morrison et al.
(1991) suggested that tyrosine binds at a distinct allosteric site.
B. subtilis PDH is inhibited competitively by tyrosine and non-
competitively by tryptophan and HPP (Champney & Jensen, 1970).
B. subtilis PDH has a C-terminal fusion of an ACTregulatory domain.
The ACT domain was ﬁrst identiﬁed in 1995 and is a small-molecule
binding domain that is found in enzymes involved in amino-acid
metabolism and transcription regulation. Small-molecule binding to
the ACT domain is thought to control the enzyme activity through
allosteric regulation. Thus, the noncompetitive inhibition by trypto-
phan and HPP in B. subtilis PDH might be a consequence of the
presence of the ACT domain. Crystal structures of PDH enzymes
from our study and from Aquifex aeolicus (Sun et al., 2009) both
revealed bound tyrosine, but only at the active site, which supports
the role of tyrosine as a competitive inhibitor. The source of tyrosine
in these two structures originated from protein expression and co-
crystallization, respectively. Not all TyrA enzymes are inhibited by
tyrosine; Synechocystis ADH, for example, is completely insensitive
to competitive inhibition by tyrosine (Legrand et al., 2006). Studies on
A. aeolicus PDH (Sun et al., 2009) showed that His217 is critical for
the inhibitory effect of tyrosine where a His217Ala mutation
completely abolished the inhibitory effect of tyrosine. Studies on
E. coli TyrA reported similar results, in which a His257Ala mutation
(His257 is equivalent to His217 in A. aeolicus PDH) abolished inhi-
bition by tyrosine (Christendat et al., 1998). Comparison of the crystal
structure of Synechocystis ADH with that of A. aeolicus PDH
revealed that Val182 is present in this location, which could account
for the loss of tyrosine inhibition.
Studies of the enzymatic mechanisms of TyrA enzymes have
revealed some variations in the reaction pathway. The kinetic data for
Synechocystis ADH suggested a sequential substrate-binding event in
which arogenate ﬁrst binds to the protein, followed by the cofactor
structural communications
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Figure 1
Tyrosine biosynthetic pathway. The ﬁgure is modiﬁed from The Enzyme Database (http://www.enzyme-database.org).(Beller et al., 2006), whereas kinetic studies on E. coli and Arabi-
dopsis thaliana suggested a random addition of NAD
+ and prephe-
nate (Sampathkumar & Morrison, 1982; Rippert & Matringe, 2002).
Kinetic studies using
13C-labeled substrates suggested a mechanism
in which decarboxylation and proton transfer occur in a concerted
manner (Hermes et al., 1984). Kinetic and mutagenesis studies of
several systems have identiﬁed key active-site residues (Christendat
et al., 1998; Christendat & Turnbull, 1999). Conserved histidine,
arginine and serine residues are critical for enzyme activity. For
instance, in E. coli TyrA His197 has been proposed to facilitate
hydride transfer from prephenate to NAD
+ by polarizing the 4-OH
group of prephenate, whereas Arg294 is critical for substrate binding.
A His197Ala mutation decreased the dehydrogenase activity signif-
icantly and an Arg294Gln mutation greatly increased the Km, but did
not affect the kcat.I nA. aeolicus PDH, Ser126 is hydrogen bonded to
the 40-OH of tyrosine and to NAD
+ and could participate in both
catalysis and ligand binding. The Ser126Ala mutation reduced kcat
15-fold and increased Km tenfold.
The TyrA gene from Haemophilus inﬂuenza Rd KW20 encodes a
bifunctional enzyme, chorismate mutase (EC 5.4.99.5)/prephenate
dehydrogenase (EC 1.3.1.12) (CM/PDH), with a molecular weight of
43 kDa (residues 1–377) and a calculated isoelectric point of 5.56. The
crystal structure of the prephenate dehydrogenase component
(HinfPDH; residues 81–377) of this TyrA enzyme was determined in
complex with tyrosine and NAD
+ at 2.0 A ˚ resolution and represents
the ﬁrst PDH structure from a bifunctional TyrA enzyme. The
structure was determined using the semi-automated high-throughput
pipeline of the Joint Center for Structural Genomics (JCSG; Lesley
et al., 2002) as part of the National Institute of General Medical
Sciences’ Protein Structure Initiative (PSI; http://www.nigms.nih.gov/
Initiatives/PSI/).
2. Materials and methods
2.1. Protein production and crystallization
Clones were generated using the Polymerase Incomplete Primer
Extension (PIPE) cloning method (Klock et al., 2008). The gene
encoding HinfPDH (GenBank AAC22939, gi|1574749; Swiss-Prot
TYRA) was ampliﬁed by polymerase chain reaction (PCR) from
H. inﬂuenzae Rd KW20 genomic DNA using PfuTurbo DNA poly-
merase (Stratagene) and I-PIPE (Insert) primers (forward primer,
50-ctgtacttccagggcATGCGTGAATCCTATGCCAATGAAAACC-30;
reverse primer, 50-aattaagtcgcgttaGCATAAAACGGCGTAGAA-
CATCTTCAAT-30; target sequence in upper case) that included
sequences for the predicted 50 and 30 ends. The expression vector
pSpeedET, which encodes an amino-terminal tobacco etch virus
(TEV) protease-cleavable expression and puriﬁcation tag (MG-
SDKIHHHHHHENLYFQ/G), was PCR-ampliﬁed with V-PIPE
(Vector) primers. The V-PIPE and I-PIPE PCR products were mixed
to anneal the ampliﬁed DNA fragments together. E. coli GeneHogs
(Invitrogen) competent cells were transformed with the V-PIPE/
I-PIPE mixture and dispensed onto selective LB–agar plates. The
cloning junctions were conﬁrmed by DNA sequencing. Using the
PIPE method, the part of the gene encoding residues Met1–Phe80
was excluded from the ﬁnal construct. Expression was performed in
selenomethionine-containing medium with suppression of normal
methionine synthesis (Van Duyne et al., 1993). At the end of
fermentation, lysozyme was added to the culture to a ﬁnal concen-
tration of 250 mgm l
 1 and the cells were harvested and frozen. After
one freeze–thaw cycle, the cells were sonicated in lysis buffer [50 mM
HEPES pH 8.0, 50 mM NaCl, 10 mM imidazole, 1 mM tris(2-car-
boxyethyl)phosphine–HCl (TCEP)] and the lysate was clariﬁed by
centrifugation at 32 500g for 30 min. The soluble fraction was passed
over nickel-chelating resin (GE Healthcare) pre-equilibrated with
lysis buffer, the resin was washed with wash buffer [50 mM HEPES
pH 8.0, 300 mM NaCl, 40 mM imidazole, 10%(v/v) glycerol, 1 mM
TCEP] and the protein was eluted with elution buffer [20 mM
HEPES pH 8.0, 300 mM imidazole, 10%(v/v) glycerol, 1 mM TCEP].
The eluate was buffer-exchanged with TEV buffer (20 mM HEPES
pH 8.0, 200 mM NaCl, 40 mM imidazole, 1 mM TCEP) using a PD-10
column (GE Healthcare) and incubated with 1 mg TEV protease per
15 mg of eluted protein. The protease-treated eluate was run over
nickel-chelating resin (GE Healthcare) pre-equilibrated with HEPES
crystallization buffer (20 mM HEPES pH 8.0, 200 mM NaCl, 40 mM
imidazole, 1 mM TCEP) and the resin was washed with the same
buffer. The ﬂowthrough and wash fractions were combined and
concentrated to 19.6 mg ml
 1 by centrifugal ultraﬁltration (Millipore)
for crystallization trials. HinfPDH was crystallized using the nano-
droplet vapor-diffusion method (Santarsiero et al., 2002) with stan-
dard JCSG crystallization protocols (Lesley et al., 2002). Sitting drops
composed of 200 nl protein mixed with 200 nl crystallization solution
were equilibrated against a 50 ml reservoir at 293 K for 28 d prior to
harvest. The crystallization reagent was composed of 0.04 M potas-
sium dihydrogen phosphate, 20.0%(v/v) glycerol and 16.0%(w/v)
PEG 8000. A rod-shaped crystal of approximate dimensions 0.1  
0.05   0.05 mm was harvested for data collection. No additional
cryoprotectant was added to the crystal. Initial diffraction screening
was carried out using the Stanford Automated Mounting system
(SAM; Cohen et al., 2002) at the Stanford Synchrotron Radiation
structural communications
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Table 1
Summary of crystal parameters, data-collection and reﬁnement statistics for
HinfPDH (PDB code 2pv7).
Values in parentheses are for the highest resolution shell.
 1 MADSe  2 MADSe
Space group P41212
Unit-cell parameters (A ˚ ) a = b = 127.79, c = 100.62
Data collection
Wavelength (A ˚ ) 0.9792 0.9184
Resolution range (A ˚ ) 29.7–2.00 (2.07–2.00) 29.7–2.00 (2.07–2.00)
No. of observations 411204 412324
No. of unique reﬂections 56589 56593
Completeness (%) 99.6 (98.8) 99.7 (99.3)
Mean I/ (I) 12.4 (2.5) 12.9 (2.6)
Rmerge on I† (%) 6.3 (51.5) 6.2 (50.7)
Rmeas on I‡ (%) 7.3 (60.5) 7.2 (59.5)
Model and reﬁnement statistics
Data set used in reﬁnement  2 MADSe
Resolution range (A ˚ ) 29.7–2.00
Cutoff criterion |F|>0
No. of reﬂections (total) 56541
No. of reﬂections (test) 2870
Completeness 99.8
Rcryst§ 0.161
Rfree} 0.194
Stereochemical parameters
Restraints (r.m.s.d. observed)
Bond angles ( ) 1.61
Bond lengths (A ˚ ) 0.017
Average isotropic B value (A ˚ 2) 35.4††
ESU‡‡ based on Rfree (A ˚ ) 0.12
Protein residues/atoms 556/4427
Water molecules/ligands 393/4
† Rmerge =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ.‡ Rmeas =
P
hkl½N=ðN   1Þ 
1=2
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ (Diederichs & Karplus, 1997). § Rcryst = P
hkl
   jFobsj j Fcalcj
   =
P
hkl jFobsj, where Fcalc and Fobs are the calculated and observed
structure-factor amplitudes, respectively. } Rfree isthe same as Rcryst but for 5.1% of the
total reﬂections that were chosen at random and omitted from reﬁnement. †† This
value represents the total B that includes TLS and residual B components. ‡‡ The
estimated overall coordinate error (Collaborative Computational Project, Number 4,
1994; Cruickshank, 1999).Lightsource (SSRL, Menlo Park, California, USA). The crystal was
indexed in the tetragonal space group P41212. The oligomeric state of
HinfPDH was determined to be a dimer by gel ﬁltration using a
0.8   30 cm Shodex Protein KW-803 column (Thomson Instruments)
equilibrated in 20 mM Tris, 200 mM NaCl, 0.5 mM TCEP pH 7.5 and
pre-calibrated with gel-ﬁltration standards (Bio-Rad). Protein con-
centrations were determined using the Coomassie Plus assay (Pierce).
2.2. Data collection, structure solution and refinement
Multiple-wavelength anomalous diffraction (MAD) data were
collected on beamline 11-1 at the SSRL using a 0.1   0.1 mm X-ray
beam at wavelengths corresponding to the inﬂection ( 1) and remote
( 2) wavelengths of a selenium MAD experiment. The data sets were
collected at 100 K using a Rayonix MAR Mosaic MX-325 CCD
detector.The MAD data were integrated and reduced using XDS and
scaled with the program XSCALE (Kabsch, 1993, 2010a,b). An initial
substructure solution was obtained with SHELXD (Sheldrick, 2008)
and the phases were reﬁned using autoSHARP (Vonrhein et al.,
2007), which gave a mean ﬁgure of merit of 0.48 with 14 selenium
sites. Automated model building was performed with ARP/wARP
(Cohen et al., 2004). Model completion and reﬁnement were per-
formed with Coot (Emsley & Cowtan, 2004) and REFMAC 5.2 (Winn
et al., 2003) using the high-energy remote ( 2) data set. The reﬁne-
ment included phase restraints from SHARP and TLS reﬁnement
with three TLS groups per chain. CCP4 programs were used for data
conversion and other calculations (Collaborative Computational
Project, Number 4, 1994).
During structure reﬁnement, additional electron density was found
at the active site. The density was well deﬁned and could be unam-
structural communications
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Figure 2
Structure of HinfPDH. (a) Ribbon diagram of a HinfPDH monomer complexed with NAD
+ and a tyrosine molecule. Helices  1– 12 and strands  1– 7 are indicated. The
C-terminal domain is colored green and the helices and  -strands of the N-terminal domain are colored cyan and red, respectively. Bound tyrosine and NAD
+ molecules are
shown in ball-and-stick representation; C, O, N and phosphate atoms are colored yellow, red, blue and orange, respectively. (b) Ribbon diagram of the HinfPDH dimer;
monomer A is colored green and monomer B is colored orange. Helices are shown as cylinders. (c) Top view compared with (b) of the HinfPDH dimer. (d) Diagram showing
the secondary-structure elements of HinfPDH superimposed on its primary sequence. The labeling of secondary-structure elements is in accord with PDBsum (http://
www.ebi.ac.uk/pdbsum), where  -helices (H1–H12) and  -strands ( 1– 7) are sequentially labeled,  -turns and  -turns are designated by Greek letters ( ,  ) and  -hairpins
are indicated by red loops.biguously assigned to a tyrosine molecule and an NAD
+ cofactor. As
these molecules were not added during the crystallization experi-
ment, they must have been acquired during protein expression and
have remained bound during puriﬁcation and crystallization. Data-
collection and reﬁnement statistics are summarized in Table 1.
2.3. Validation and deposition
The quality of the crystal structure was analyzed using the JCSG
Quality Control server (http://smb.slac.stanford.edu/jcsg/QC). This
server veriﬁes the stereochemical quality of the model using Auto-
DepInputTool (Yang et al., 2004), MolProbity (Chen et al., 2010) and
WHATIF v.5.0 (Vriend, 1990), the agreement between the atomic
model and the data using SFCHECK v.4.0 (Vaguine et al., 1999) and
RESOLVE (Terwilliger, 2004), the protein sequence using ClustalW
(Thompson et al., 1994), the atom occupancies using MOLEMAN2
(Kleywegt, 2000) and the consistency of NCS pairs. Protein
quaternary-structure analysis was conducted using the PISA server
(http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html; Krissinel &
Henrick, 2005). Fig. 2(d) was adapted from PDBsum (Laskowski,
2009); all other ﬁgures were prepared with PyMOL (DeLano, 2002).
Atomic coordinates and experimental structure factors have been
deposited in the PDB under accession code 2pv7.
3. Results and discussion
3.1. Overall structure
The ﬁnal model consists of a dimer of the PDH domain of TyrA
(residues 92–371 for chains A and B), two nicotinamide adenine
dinucleotides (NAD
+), two tyrosines and 393 water molecules in the
asymmetric unit (Figs. 2a,2 b and 2c). No electron density was
observed for Gly80–Phe91, Asp312–Glu315 and Asn372–Gly377 in
chain A and Gly80–Val91 and Asn372–Gly377 in chain B. The side
chains of Lys212 and Lys348 from chain A and of Arg132, Lys212,
Lys239, Gln325 and Ala371 from chain B were omitted owing to poor
electron density. The Matthews coefﬁcient (VM; Matthews, 1968) was
2.98 A ˚ 3 Da
 1 and the estimated solvent content was 58.7%. The
Ramachandran plot produced by MolProbity showed that 98% of the
residues are in favored regions, with no outliers.
Each monomer consists of an N-terminal  /  dinucleotide-binding
domain (residues 92–243) and a C-terminal  -helical dimerization
domain (residues 244–371) (Fig. 2a). The active site is located at the
domain interface. The N-terminal domain adopts a modiﬁed Ross-
mann fold, which consists of a parallel seven-stranded  -sheet (strand
order  2- 1- 3- 4- 5- 6- 7) with the  1 helix on one face of the
 -sheet and the  2,  3,  4 and  5 helices on the other. Structural
comparisons of HinfPDH and other nucleotide-binding proteins,
including other TyrA enzymes, show that HinfPDH lacks the  – 
structural motif between  2 and  2 that is present and is part of the
 -sheet in other nucleotide-binding proteins. The C-terminal domain
consists of seven helices ( 6– 12) that form the dimer interface; the
helices from each monomer are intertwined into a tightly packed
helical bundle with a buried surface of 11 000 A ˚ 2 (Figs. 2b and 2c).
The two monomers are structurally similar to each other, with an
r.m.s.d. of 0.2 A ˚ for 268 equivalent C
  atoms.
3.2. The active site
The active site is located in the cleft between the N- and C-terminal
domains (Figs. 2a,2 b and 2c). One tyrosine and one NAD
+ are bound
in each monomer (Fig. 3a). His200, Ser179 and Arg297 (Fig. 3b) are
among the important residues for enzyme catalysis and/or ligand
binding and are conserved in TyrA enzymes across all kingdoms of
life. The His200 imidazole is hydrogen bonded to the 40-OH of the
bound tyrosine. Ser179 hydrogen bonds to both the ribose O atom of
nicotinamide nucleoside and the 40-OH of the bound tyrosine and is
important for orientating prephenate and NAD
+ for catalysis. The
Arg297 guanadinium forms a pair of electrostatic interactions with
the tyrosine carboxyl, which also interacts with Gln301 from the  8
helix. The tyrosine amino group hydrogen bonds to Tyr306 from  9
and Tyr2880 from  8 of the adjacent monomer. His260 is located close
to the tyrosine amino group and could be involved in regulation of
tyrosine inhibition in a similar way to His217 in A. aeolicus.
The aromatic ring of the bound tyrosine packs against the nico-
tinamide ring of NAD
+ such that the 40-OH of tyrosine is approxi-
mately 4 A ˚ away from C4 of the nicotinamide ring. Assuming that
prephenate adopts the same binding mode, the structure suggests that
the hydride is transferred from prephenate to the si face of NAD
+,
which is consistent with a previous proton NMR study on the E. coli
TyrA enzyme using isotope-labeled NAD-4-d (Hermes et al., 1984).
The binding mode of NAD
+ is similar to those of arogenate de-
hydrogenase from Synechocystis sp. and prephenate dehydrogenase
from A. aeolicus (Legrand et al., 2006; Sun et al., 2006). The pyro-
phosphate of NAD
+ interacts with the P-loop (Gly108–Gly113)
between  1 and  1, forming hydrogen bonds to Lys111 and the main-
chain amides of Lys111 and Leu112. The diol of the adenylyl ribose
structural communications
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Figure 3
Active site of HinfPDDH. (a) Final model of tyrosine and NAD
+ molecules ﬁtted
in 2Fo   Fc electron-density maps prior to model building as output from the last
step of XSOLVE (JCSG, unpublished work). The map is contoured at 1 .( b)
Active site of HinfPDDH showing key active-site residues and the bound tyrosine
and NAD
+ molecules in ball-and-stick representation. C atoms are colored gray for
the protein and yellow for the ligands; O, N and phosphate atoms are colored red,
blue and orange, respectively.hydrogen bonds to Asp131 and Lys132 from the loop located
between  2 and  2. The adenine ring is sandwiched between Val152
and Arg132 from helices  2 and  3, with its N1 hydrogen bonded to
Trp135 from  2. The diol of the nicotinamide ribose is hydrogen
bonded to Ser179 and Val152. The nicotinamide ring interacts with
the protein mainly through hydrophobic interactions.
3.3. Structural comparison with other TyrA enzymes
A search with FATCAT (Ye & Godzik, 2004) using the HinfPDH
coordinates identiﬁed the closest structural homologues of HinfPDH
in the PDB as the prephenate dehydrogenases from A. aeolicus
(AaeoPDH; PDB code 2g5c; Sun et al., 2006) and Streptococcus
thermophilus (SthePDH; PDB code 3dzb; Z. Zhang, S. Eswara-
moorthy, S. K. Burley & S. Swaminathan, unpublished work) and the
arogenate dehydrogenase from Synechocystis sp. (SyneADH; PDB
code 2f1k; Legrand et al., 2006). HinfPDH is bifunctional, whereas
the other three enzymes are monofunctional. The pairwise sequence
identities between HinfPDH and AaeoPDH, SthePDH and
SyneADH are 20, 27 and 25%, respectively. Despite the low sequence
identity, the overall structures of these enzymes are very similar. The
structures of AaeoPDH complexed with the ligands NAD
+ (PDB
code 2g5c), NAD
+ and l-tyrosine (PDB code 3ggg), NADH and 4-
hydroxylphenylpyruvate (HPP; PDB code 3ggo) and NAD
+ and 4-
hydroxyphenylpropionate (PDB code 3ggp) are available (Sun et al.,
2009), but only the ﬁrst two structures were used for comparison
because they are sufﬁcient to represent the two unique enzyme states;
they are denoted AaeoPDH and AaeoPDH–Tyr–NAD
+, respectively.
SyneADH has an NADP
+ bound at the active site and SthePDH has
no ligand bound. The dehydrogenase activity of SyneADH is strictly
dependent on arogenate and NADP
+ (Legrand et al., 2006).
Conversely, NAD
+ and prephenate are the preferred cofactor and
substrate for AaeoPDH, although a very low level of dehydrogenase
activity is detected when NADP
+ with prephenate or NAD
+ with
arogenate are used (Bonvin et al., 2006).
Although the overall fold is similar, structural comparisons
revealed important differences around the active site. Compared with
other TyrA enzymes, HinfPDH lacks an  – structural motif between
 2 and  2, the loop between  5 and  6( L  5– 6) is much shorter, and
an extra helix  12 is found at the C-terminus (Fig. 4). Multiple
sequence alignment of many representative TyrA proteins clearly
shows that the  –  motif and L 5– 6 represent unique structural
differences between bifunctional and monofunctional TyrA enzymes
(Fig. 5), but the extra C-terminal helix is less obviously discernable
from the sequence comparisons, presumably because the exact end
point of the prephenate dehydrogenase domain is difﬁcult to deter-
mine for cases such as TyrA-aroFor TyrA-ACT fusions in which aroF
and ACT are fused at the C-terminal end.
In HinfPDH, L 5– 6 is eight residues shorter than in AaeoPDH,
SthePDH and SyneADH. This loop is well ordered in the HinfPDH,
AaeoPDH and SyneADH structures (Fig. 4c) but is disordered in the
SthePDH structure owing to the absence of bound cofactor. In
AaeoPDH and SyneADH, this loop extends along the cofactor-
binding site. Ser155 in AaeoPDH and Gln120 in SyneADH are in
structurally equivalent positions (Fig. 4c) and both form hydrogen
bonds to the pyrophosphate O atom of the bound cofactor. However,
structural communications
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Figure 4
Structural differences between HinfPDH and its structural homologues. (a) Superimposition of HinfPDH, AaeoPDH, SthePDH and SyneADH reveals unique structural
differences in HinfPDH including a missing  –  motif, a shorter L 5– 6 loop, and an extra C-terminal helix. HinfPDH is colored green or orange for each monomer. The
AaeoPDH, SthePDH and SyneADH structures are colored magenta, yellow and blue, respectively. Bound tyrosine and NAD
+ molecules are shown in ball-and-stick
representation. (b) Enlarged view of the area around the  –  motif showing that HinfPDH is missing the  –  motif compared with AaeoPDH, SthePDH and SyneADH. (c)
Enlarged view of the area around L 5– 6. Lys111 of HinfPDH is shown with a green backbone, Ser155 of AaeoPDH is in magenta and Gln120 of SyneADH is in blue. (d)
Enlarged view of the C-terminal area showing that an extra C-terminal helix is present in HinfPDH. The  7 and  8 helices of HinfPDH superimposed onto structurally
equivalent helices in AaeoPDH, SthePDH and SyneADH are also indicated.in HinfPDH no residue is structurally equivalent because of the
shorter loop and Lys111 from  1 instead provides the equivalent
interaction with the pyrophosphate O atom (Fig. 4c). The equivalent
residues to Lys111 in AaeoPDH and SyneADH are Phe40 and Leu10,
respectively, and neither side chain can form hydrogen bonds to the
pyrophosphate. This suggests that although a shorter L 5– 6 loop has
evolved in HinfPDH, the ability to bind cofactor is not affected.
In SyneADH, the phosphate group of the adenosine ribose of
NADP
+ is recognized by helical residues in the  –  motif. The
phosphate group is stabilized by electrostatic interaction with Arg31
and hydrogen-bonding interactions with Gln32 and Thr35, as well as
with the main chain of Arg31 and Gln32. The equivalent residues in
AaeoPDH are Ile63, Asn64 and Ser67. A loss of electrostatic inter-
action caused by the substitution of Arg by Ile may explain why
AaeoPDH prefers NAD
+ over NADP
+ as cofactor. In SthePDH, the
equivalent residues are Arg36, Ser37 and Ser40. Thus, the ability to
form electrostatic and hydrogen-bonding interactions is similar to
that of SyneADH, suggesting that SthePDH is capable of binding
NADP
+.I nHinfPDH, Arg132 is structurally equivalent to SyneADH
Arg31, but residues equivalent to Gln32 and Thr35 are absent owing
to the lack of the  –  structural motif. It is possible that HinfPDH
also prefers NAD
+ over NADP
+ in a manner similar to bifunctional
TyrA enzymes from E. coli and K. pneumonia.
A smaller local difference among these TyrA structures is the loop
joining  7 and  8 and the adjacent residues (Fig. 4d). This loop takes
a wider turn in HinfPDH compared with that in AaeoPDH, SthePDH
and SyneADH and is positioned next to  12. Ser284–Leu290 in this
region are highly conserved in TyrAc_ sequences, suggesting that
they play important roles.
3.4. Global conformational change
Another important difference between HinfPDH and other TyrA
structures is the relative orientation of the respective N- and
C-terminal domains. Pairwise structural alignment of HinfPDH with
AaeoPDH, AaeoPDH–Tyr–NAD
+, SthePDH and SyneADH using
only the N-terminal domain gives r.m.s.d.s of 1.8, 1.7, 1.9 and 1.5 A ˚ ,
respectively, for 128–132 superimposed C
  atoms (0.8–0.9 A ˚ for core
 -sheet residues). Upon structural superimposition, it is immediately
noticeable that differences in the relative orientation of the N- and
C-terminal domains are present in these TyrA structures (Figs. 6a and
6b). A hinge region around Glu242–Asn244 connects the N- and
C-terminal domains at the domain interface opposite to the
substrate-binding site. Superimposition using the C-terminal domain
gives similar results, although the results are less obvious owing to
internal structural differences within the C-terminal domains of these
TyrA structures. Therefore, the discussion below is based on super-
impositions using the N-terminal domain.
Using the C-terminal domain of HinfPDH as a reference, the
C-terminal domains of AaeoPDH, SthePDH and SyneADH are
farther away from the substrate-binding site; therefore, HinfPDH
represents the most closed form, SyneADH is the most open form
and AaeoPDH and SthePDH are in intermediate states (Figs. 6a and
6b). Monomer B of AaeoPDH–Tyr–NAD
+ has both NAD
+ and
tyrosine bound and the conformation is closed, similar to HinfPDH.
Monomer A of AaeoPDH–Tyr–NAD
+ only has NAD
+ bound and the
conformation is similar to AaeoPDH. Comparison of the AaeoPDH
and AaeoPDH–Tyr–NAD
+ structures suggest that tyrosine induces a
conformational change upon binding. Hence, it is possible that the
binding of tyrosine to HinfPDH also induces a conformational
change from an open to a closed form and the closed form is captured
in the current HinfPDH structure. A crystal structure of apo
HinfPDH could provide direct evidence for this proposal. In the
closed conformation,  6,  8,  9 and  80 ( 8 from monomer B) are
close to the bound tyrosine and  8 and  120 ( 12 from monomer B)
are near L 5– 6, facilitating closure of the active site and the proper
alignment of active-site residues for catalysis. Key active-site residues
in this region include His260 ( 6), Arg297, Gln301 ( 8), Tyr2880
( 80), Tyr306 ( 9), Arg3650 ( 120) and Asp206 (L 5– 6). If a tyrosine
molecule is modeled adjacent to the cofactor in AaeoPDH and
SthePDH, the residue equivalent to Arg297 of HinfPHDH is too
distant to interact with the tyrosine. The conformational change is
structural communications
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Figure 5
Multiple sequence alignment of representative TyrA enzymes. Regions around the  –  motif and L 5– 6 are shown. Abbreviations: Hinf, Haemophilus inﬂuenzae Rd KW20;
Etas, Erwinia tasmaniensis Et1/99; Ecol, Escherichia coli str. K-12 substr. MG1655; Plum, Photorhabdus luminescens subsp. laumondii TTO1; Pmul, Pasteurella multocida
subsp. multocida str. Pm70; Vcho, Vibrio cholerae O1 biovar eltor str. N16961; Vpar, Vibrio parahaemolyticus RIMD 2210633; Yent, Yersinia enterocolitica subsp.
enterocolitica 8081; Aful, Archaeoglobus fulgidus; Syne, Synechocystis sp. (Legrand et al., 2006); Atha, Arabidopsis thaliana (Rippert & Matringe, 2002); Npun, Nostoc
punctiforme PCC 73102 (Song et al., 2005); Zmob, Zymomonas mobilis (Zhao et al., 1993); Paer, Pseudomonas aeruginosa PA7 (Xia & Jensen, 1990); Pstu, Pseudomonas
stutzeri (Xie et al., 2000); Aaeo, Aquifex aeolicus VF5 (Bonvin et al., 2006); Bsub, Bacillus subtilis (Champney & Jensen, 1970); Sthe: Streptococcus thermophilus LMG 18311
(Song et al., 2005); Efae, Enterococcus faecalis V583 (Song et al., 2005).independent of cofactor binding as the structures of SyneADH with
NADP
+ bound, AaeoPDH with NAD
+ bound and SthePDH without
any cofactor are all in similar open conformations.
In the closed conformation of HinfPDH an ionic network con-
sisting of Arg297, a bridging water molecule, Asp206 from L 5– 6 and
Arg3650 from  120 is observed that may be involved in gating the
active site (Fig. 6c). The bridging water is present in both monomers.
The Arg3650 side chain adopts dual conformations, with one con-
formation participating in the ionic network and the other pointing
away from the active site. This dual conformation may be part of the
gating mechanism, in which an ionic network forms on closure of the
active site after substrate is bound and is broken when the product is
released. It is worth noting that Asp206 is absolutely conserved and
Arg365 is highly conserved in chorismate mutase/prephenate dehy-
drogenase sequences but not in monofunctional TyrA enzymes. Thus,
the active-site gating mechanism might be different in bifunctional
and monofunctional TyrA enzymes.
3.5. Insights into the catalytic mechanism
Previous studies on the pH-dependence of the E. coli TyrA enzyme
showed that a catalytic group with a pKa value of about 6.5 is de-
protonated for dehydrogenase activity (Turnbull, Cleland et al.,
1991). Subsequent site-directed mutagenesis experiments revealed
that this critical catalytic residue is His197 (Christendat et al., 1998).
The catalytic mechanism of the oxidative decarboxylation of E. coli
TyrAwas investigated and suggested a concerted mechanism in which
hydride transfer and decarboxylation occur in a concerted manner. It
was proposed that His197 provides the driving force for the dehy-
drogenase reaction by polarizing the 40-hydroxyl group of prephenate
(Christendat et al., 1998). It was also postulated that since the end-
product of the reaction is aromatic, polarization of the 40-OH group is
sufﬁcient to lower the energy barrier for the reaction, rather than
deprotonation of the 40-OH group to form a  -keto acid intermediate
in a stepwise mechanism. The crystal structure of HinfPDH shows
that the N
"2 atom of His200 (equivalent to His197 in E. coli TyrA) is
hydrogen bonded to the 40-hydroxyl group of tyrosine at a distance of
 2.6 A ˚ . A hydrogen-bonding network between His200, His248 and
Asp249 is observed in which His200 N
 1 hydrogen bonds to
His248 N(H)
"2 and His248 N(H)
 1 hydrogen bonds to Asp249 O
 1.
Asp249 is located near the protein surface. As for His200, His248 and
Asp249 are highly conserved in TyrA sequences. This hydrogen-
bonding network can help to maintain His200 N
"2 in a deprotonated
state. The Ser179 hydrogen bond to the 40-OH of the bound tyrosine
can provide an additional driving force for the reaction by polarizing
the 40-OH group since the equivalent Ser126 in AaeoPDH is critical
for catalysis. In addition, HinfPDH and E. coli TyrA share 57%
sequence identity in their prephenate dehydrogenase domains and all
key active-site residues are conserved. Hence, HinfPDH is likely to
adopt a concerted mechanism for dehydrogenase reaction as found
for E. coli TyrA. In HinfPDH, tyrosine is bound directly at the
catalytic site, suggesting that it acts as a competitive inhibitor.
How TyrA enzymes evolved to be speciﬁc for prephenate or
arogenate is intriguing because prephenate and arogenate have very
similar structures. In HinfPDH, Gln301, Tyr306, Tyr288 and His260
are positioned close to the amino and carboxyl groups of the bound
tyrosine and could be involved in substrate speciﬁcity (Fig. 6c).
Gln301, Tyr306 and Tyr288 are highly conserved in bifunctional TyrA
sequences. In other TyrA sequences, Gln301 is replaced by Gly, Ser or
Thr. Tyr306 is relatively conserved as Trp in TyrAp and TyrAc, but is
Trp, Gly or Val in TyrAa. Tyr288 is located at the N-terminus of  8,
where some local structural differences are found between HinfPDH
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Figure 6
Superimposition of TyrA structures showing differences in the relative orientation
of the N- and C-terminal domains and a close-up view of the active site of
HinfPDH. (a) Superimposition of HinfPDH, AaeoPDH, AaeoPDH–Tyr–NAD
+,
SthePDH and SyneADH reveals differences in the relative orientation of the N-
and C-terminal domains in these TyrA proteins. HinfPDH, AaeoPDH, AaeoPDH
(monomer B)–Tyr–NAD
+, SthePDH and SyneADH are colored green, magenta,
orange, cyan and blue, respectively. (b) Same orientation as (a); for clarity, only
HinfPDH and SyneADH are shown. (c) An ionic network in the active site of
HinfPDH consists of Arg297, a bridging water molecule, Asp206 and Arg3650 from
adjacent molecule in a dual conformation. His260, Tyr288, Gln301 and Tyr306 that
could be involved in substrate selectivity are also shown. Hydrogen bonds are
indicated as dashed lines.and other TyrA structures. Alignment of TyrA sequences shows a gap
of approximately four residues around Tyr288 in the TyrAp, TyrAa
and TyrAc sequences. His260 is conserved in TyrA, except for some
TyrAas, where it is Val or Gln. Given the structural resemblance
between prephenate and arogenate, further experiments to elucidate
the exact prephenate-binding mode will advance our understanding
of substrate speciﬁcity in TyrA enzymes.
4. Conclusions
HinfPDH is the ﬁrst prephenate dehydrogenase structure to be
determined from a bifunctional TyrA enzyme. This structure reveals
active-site residues that are important for catalysis and/or ligand
binding and are consistent with previously determined structures of
other TyrA enzymes. The comparison of HinfPDH with other known
TyrA structures indicates important differences that appear to be
characteristic features that differentiate the bifunctional and mono-
functional TyrA enzymes and suggest that the regulation of enzyme
activity is likely to differ between bifunctional and monofunctional
TyrA enzymes. These structural differences may be related to the
presence of a chorismate mutase domain in the bifunctional TyrA
enzymes. A crystal structure of full-length H. inﬂuenzae TyrA should
provide insight into this question. Additional information about the
proteins described in this study is available from TOPSAN (Krishna
et al., 2010) at http://www.topsan.org/explore?PDBid=2pv7.
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